4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The tall cell (TC) variant of papillary thyroid carcinoma (PTC) has an unfavorable prognosis. The diagnostic criteria remain inconsistent, and the role of a minor TC component is unclear. Molecular diagnostic markers are not available; however, there are two potential candidates: BRAF V600E and telomerase reverse transcriptase (TERT) promoter mutations. Using a novel approach, we enriched a collective with PTCs that harbored an adverse outcome, which overcame the limited statistical power of most studies. This enabled us to review 125 PTC patients, 57 of which had an adverse outcome. The proportion of TCs that constituted a poor prognosis was assessed. All of the tumors underwent sequencing for TERT promoter and BRAF V600E mutational status and were stained with an antibody to detect the BRAF V600E mutation. A 10% cutoff for TCs was significantly associated with advanced tumor stage and lymph node metastasis. Multivariate analysis showed that TCs above 10% were the only significant factor for overall, tumor-specific, and relapse-free survival. Seven percent of the cases had a TERT promoter mutation, whereas 61% demonstrated a BRAF mutation. The presence of TC was significantly associated with TERT promoter and BRAF mutations. TERT predicted highly significant tumor relapse (P<0.001). PTCs comprised of at least 10% TCs are associated with an adverse clinical outcome and should be reported accordingly. BRAF did not influence patient outcome. Nevertheless, a positive status should encourage the search for TCs. TERT promoter mutations are a strong predictor of tumor relapse, but their role as a surrogate marker for TCs is limited.

          Related collections

          Author and article information

          Journal
          Endocr. Relat. Cancer
          Endocrine-related cancer
          1479-6821
          1351-0088
          Jun 2015
          : 22
          : 3
          Affiliations
          [1 ] Institute of PathologyUniversity of Bern, Murtenstrasse 31, 3010 Bern, SwitzerlandDivision of Nuclear MedicineUniversity Hospital Zurich, Zurich, SwitzerlandDepartment of NeuropathologyInstitute of Pathology, German Cancer Research Center (DKFZ), Ruprecht-Karls University, and Clinical Cooperation Unit Neuropathology, Heidelberg, GermanyInstitute of Surgical PathologyUniversity Hospital Zurich, Zurich, SwitzerlandInstitute of Surgical PathologyTriemlispital, Zürich, Switzerland dettmerms@gmail.com matthias.dettmer@pathology.unibe.ch.
          [2 ] Institute of PathologyUniversity of Bern, Murtenstrasse 31, 3010 Bern, SwitzerlandDivision of Nuclear MedicineUniversity Hospital Zurich, Zurich, SwitzerlandDepartment of NeuropathologyInstitute of Pathology, German Cancer Research Center (DKFZ), Ruprecht-Karls University, and Clinical Cooperation Unit Neuropathology, Heidelberg, GermanyInstitute of Surgical PathologyUniversity Hospital Zurich, Zurich, SwitzerlandInstitute of Surgical PathologyTriemlispital, Zürich, Switzerland.
          Article
          ERC-15-0057
          10.1530/ERC-15-0057
          25870252
          28fb3f00-57c7-4c68-9d63-c514bbefed95
          © 2015 Society for Endocrinology.
          History

          BRAF,TERT,diagnostic criteria,papillary thyroid carcinoma,prognosis,tall cell

          Comments

          Comment on this article